Since
2009
Jiangsu Aidea Pharmaceutical Group Co., Ltd. was established in 2009 and listed on the STAR Market of the Shanghai Stock Exchange in 2020 (Stock Code: 688488.SH). The Company is a nationally recognized High-Tech Enterprise and a National-level Specialized, Sophisticated, Distinctive, and Innovative “Little Giant” Enterprise. Focusing on anti-HIV drugs as its core business, while leveraging its competitive advantages in the Human-derived protein field, the Company is actively engaged in the R&D, production, and sales of innovative drugs. It has undertaken 3 projects under the “National New Drug Innovation” Major Project of China and participated in 2 projects under the “Emerging and Major Infectious Disease Prevention and Control” National Science and Technology Major Project. As of the end of 2025, the Company had over 20 pipeline projects, with 12 major projects under development, including 6 Class 1 new drugs and 5 Class 2 modified new drugs.
Aidea Pharma is committed to building a comprehensive anti-HIV product portfolio to meet evolving clinical needs. To date, the Company has launched two Class 1 new drugs: Ainuovirine Tablets (Aibangde®), China's first oral anti-HIV Class 1 new drug, and Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets (Aitribond®), China's first oral Single Tablet Regimen Class 1 new drug for HIV treatment. Both products have been included in the National Medical Insurance List and the Chinese Guidelines for the Diagnosis and Treatment of HIV/AIDS. In March 2026, the Company's first anti-HIV generic product, Dolutegravir Sodium Tablets, was approved for marketing, adding a first-line core drug to China's domestic anti-HIV armamentarium.
The Company is focused on HIV “treatment + prevention,” with a pipeline that includes multiple Class 1 new drugs. Among them, the novel integrase inhibitor ACC017 has entered Phase III clinical trials; the triple combination product ADC118, for which ACC017 is the core drug, has received clinical trial approval; an international multi-center clinical trial for the integrase inhibitor is being planned; and the long-acting pre-exposure prophylaxis (PrEP) drug ACC085 injection has received clinical trial approval.
At the same time, Aidea Pharma continues to strengthen its resource advantages in the human-derived protein sector by actively building an upstream and downstream industrial ecosystem. Through the acquisition of Nanda Pharmaceutical, the Company has established an integrated “human-derived protein API-to-drug product” layout, further reinforcing its dual-driven strategy and creating a second growth curve. In areas such as stroke, two modified new drugs—ADB116 for injection and AD108 injection—have received clinical trial approval, providing strong momentum for the Company's sustainable development.
Looking ahead, Aidea Pharma will continue to uphold its original aspiration for innovation, with sustained investment in the anti-HIV and human-derived protein fields. The Company is committed to delivering higher-quality products and services to society, continuously improving drug accessibility, contributing to the “Healthy China” initiative, and building a Chinese innovative drug brand with global influence.
